JP2024034914A - 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 - Google Patents
重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 Download PDFInfo
- Publication number
- JP2024034914A JP2024034914A JP2022139482A JP2022139482A JP2024034914A JP 2024034914 A JP2024034914 A JP 2024034914A JP 2022139482 A JP2022139482 A JP 2022139482A JP 2022139482 A JP2022139482 A JP 2022139482A JP 2024034914 A JP2024034914 A JP 2024034914A
- Authority
- JP
- Japan
- Prior art keywords
- aim
- renal failure
- uremia
- blood
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037157 Azotemia Diseases 0.000 title claims abstract description 65
- 208000009852 uremia Diseases 0.000 title claims abstract description 65
- 208000001647 Renal Insufficiency Diseases 0.000 title claims abstract description 60
- 201000006370 kidney failure Diseases 0.000 title claims abstract description 60
- 241000282324 Felis Species 0.000 title claims abstract description 49
- 239000012634 fragment Substances 0.000 claims abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 44
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 43
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 43
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 38
- 230000004071 biological effect Effects 0.000 claims abstract description 17
- 241000282326 Felis catus Species 0.000 claims description 63
- 210000004369 blood Anatomy 0.000 claims description 54
- 239000008280 blood Substances 0.000 claims description 54
- 239000002441 uremic toxin Substances 0.000 claims description 54
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 24
- 210000002540 macrophage Anatomy 0.000 claims description 17
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 12
- 239000011574 phosphorus Substances 0.000 claims description 12
- 229910052698 phosphorus Inorganic materials 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims description 7
- 239000000158 apoptosis inhibitor Substances 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 5
- 241000282693 Cercopithecidae Species 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 5
- 241000700159 Rattus Species 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 4
- 241000699800 Cricetinae Species 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract description 7
- 230000005713 exacerbation Effects 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 58
- 108090000623 proteins and genes Proteins 0.000 description 41
- 238000000034 method Methods 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 30
- 230000000694 effects Effects 0.000 description 26
- 230000003907 kidney function Effects 0.000 description 25
- 239000002585 base Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 230000036961 partial effect Effects 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 238000004422 calculation algorithm Methods 0.000 description 12
- 239000003638 chemical reducing agent Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 10
- 102000054727 Serum Amyloid A Human genes 0.000 description 9
- 101710190759 Serum amyloid A protein Proteins 0.000 description 9
- -1 aromatic amino acids Chemical class 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
- 208000020832 chronic kidney disease Diseases 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000006866 deterioration Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 241000282327 Felis silvestris Species 0.000 description 5
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 4
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000911996 Homo sapiens CD5 antigen-like Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002121 endocytic effect Effects 0.000 description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 102000051875 human CD5L Human genes 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000010149 post-hoc-test Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101710105313 Anionic trypsin Proteins 0.000 description 3
- 101710095342 Apolipoprotein B Proteins 0.000 description 3
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 3
- 241000879755 Caracal Species 0.000 description 3
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 3
- 101710197901 Galectin-3-binding protein Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000282372 Panthera onca Species 0.000 description 3
- 241000282373 Panthera pardus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108050008568 SRCR domains Proteins 0.000 description 3
- 102000000185 SRCR domains Human genes 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 102100034396 Trypsin-3 Human genes 0.000 description 3
- 102100038935 Vacuolar protein sorting-associated protein 53 homolog Human genes 0.000 description 3
- 101710148413 Vacuolar protein sorting-associated protein 53 homolog Proteins 0.000 description 3
- 229940091181 aconitic acid Drugs 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000028208 end stage renal disease Diseases 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 229940097043 glucuronic acid Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UVZICZIVKIMRNE-UHFFFAOYSA-N thiodiacetic acid Chemical compound OC(=O)CSCC(O)=O UVZICZIVKIMRNE-UHFFFAOYSA-N 0.000 description 3
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 3
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 2
- 241001455214 Acinonyx jubatus Species 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 2
- 101710122347 CD5 antigen-like Proteins 0.000 description 2
- 102100026862 CD5 antigen-like Human genes 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 241000880311 Catopuma temminckii Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 241000879808 Felis chaus Species 0.000 description 2
- 241000879809 Felis margarita Species 0.000 description 2
- 241000879813 Felis nigripes Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710015718 KIAA0100 Proteins 0.000 description 2
- 241000109849 Leopardus jacobita Species 0.000 description 2
- 241001455213 Leopardus pardalis Species 0.000 description 2
- 241000204992 Leopardus tigrinus Species 0.000 description 2
- 241000879776 Leopardus wiedii Species 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- 241000721701 Lynx Species 0.000 description 2
- 241000879775 Lynx canadensis Species 0.000 description 2
- 241001423924 Lynx pardinus Species 0.000 description 2
- 241000879777 Lynx rufus Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101100495245 Mus musculus Cd5l gene Proteins 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 241000880309 Neofelis nebulosa Species 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- 241001147389 Panthera uncia Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 241000879781 Prionailurus viverrinus Species 0.000 description 2
- 102100037163 Protein KIAA0100 Human genes 0.000 description 2
- 241000282374 Puma concolor Species 0.000 description 2
- 241001485779 Puma yagouaroundi Species 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101100395211 Trichoderma harzianum his3 gene Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000011040 acute kidney failure Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940105774 coagulation factor ix Drugs 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- IGMNYECMUMZDDF-UHFFFAOYSA-N homogentisic acid Chemical compound OC(=O)CC1=CC(O)=CC=C1O IGMNYECMUMZDDF-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- MNWUYMNVJNYHLO-UHFFFAOYSA-N 2-(2,5-dihydroxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC(O)=CC=C1O.OC(=O)CC1=CC(O)=CC=C1O MNWUYMNVJNYHLO-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 241000880313 Catopuma badia Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 241000829558 Felis silvestris bieti Species 0.000 description 1
- 241000879810 Felis silvestris lybica Species 0.000 description 1
- 241001128617 Felis silvestris silvestris Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000204959 Leopardus Species 0.000 description 1
- 241000204985 Leopardus geoffroyi Species 0.000 description 1
- 241000879779 Leopardus guigna Species 0.000 description 1
- 241001485957 Leopardus guttulus Species 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 241000721699 Lynx lynx Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241001391175 Neofelis diardi Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000880495 Otocolobus manul Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000880455 Pardofelis marmorata Species 0.000 description 1
- 101100422265 Patiria pectinifera SRCR1 gene Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001501971 Prionailurus Species 0.000 description 1
- 241001501970 Prionailurus bengalensis Species 0.000 description 1
- 241000880488 Prionailurus planiceps Species 0.000 description 1
- 241000879778 Prionailurus rubiginosus Species 0.000 description 1
- 241000880460 Profelis aurata Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000269808 Sparus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 230000013227 macrophage apoptotic process Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
すなわち、本発明は以下の通りである。
Apoptosis inhibitor of macrophage(AIM)、AIMの生物学的活性を有するAIM断片、又は該AIM又はAIM断片をコードする核酸を含む、重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤であって、重度腎不全が、血中のインドキシル硫酸の濃度が5μg/mL以上、且つ、血中の無機リンの濃度が7.5 mg/dL以下で定義される、剤。
[2]
Apoptosis inhibitor of macrophage(AIM)、AIMの生物学的活性を有するAIM断片、又は該AIM又はAIM断片をコードする核酸を含む、重度腎不全に罹患するネコ科動物における血中の尿毒素の濃度を低減するための剤であって、重度腎不全が、血中のインドキシル硫酸の濃度が5μg/mL以上、且つ、血中の無機リンの濃度が7.5 mg/dL以下で定義される、剤。
[3]
Apoptosis inhibitor of macrophage(AIM)、AIMの生物学的活性を有するAIM断片、又は該AIM又はAIM断片をコードする核酸を含む、哺乳動物における血中の尿毒素の濃度を低減するための剤。
[4]
哺乳動物がヒト、ウシ、サル、ウマ、ブタ、ヒツジ、ヤギ、イヌ、ネコ、モルモット、ラット、マウス、ウサギ、又はハムスターである、[3]記載の剤。
[5]
哺乳動物がヒトである、[3]記載の剤。
[重度腎不全]
本明細書において、ネコ科動物における「重度腎不全」とは、「ネコ科動物における血中のインドキシル硫酸の濃度が5μg/mL以上、且つ、血中の無機リンの濃度が7.5 mg/dL以下」と定義する。また、一態様において、ネコ科動物における重度腎不全は、「ネコ科動物における血中のインドキシル硫酸の濃度が5μg/mL以上、且つ、血中の無機リンの濃度が6.8 mg/dL以下」と定義されてもよい。このように定義される腎不全に罹患するネコ科動物は、通常、腎機能の大部分(約80~90%)が失われている状態を有する。
尚、「ネコ科動物における血中のインドキシル硫酸の濃度が5μg/mL以上、且つ、血中の無機リンの濃度が7.5 mg/dL以下」及び「ネコ科動物における血中のインドキシル硫酸の濃度が5μg/mL以上、且つ、血中の無機リンの濃度が6.8 mg/dL以下」は、いずれも、国際獣医腎臓病研究グループ(International Renal Interest Society, IRIS)が提供するネコ科動物(特にイエネコ)の慢性腎疾患のステージングにおいては、ステージ3の後期に相当する状態である。尚、IRISステージングにおいては、腎機能の95%程度が失われた状態がステージ4と分類される。
本明細書において、「ネコ科動物」とは、ネコ科(Felidae)に分類される動物を意味する。ネコ科動物としては、例えば、ライオン(Panthera leo)、ヒョウ(Panthera pardus)、トラ(Panthera tigris)、ユキヒョウ(Panthera uncia)、ジャガー(Panthera onca)、ウンピョウ(Neofelis nebulosa)、スンダウンピョウ(Neofelis diardi)、クーガー(Puma concolor)、チーター(Acinonyx jubatus)、ジャガランディ(Herpailurus yagouaroundi)、アフリカゴールデンキャット(Caracal aurata)、カラカル(Caracal caracal)、サーバル(Leptailurus serval)、ボルネオヤマネコ(Catopuma badia)、アジアゴールデンキャット(Catopuma temminckii)、マーブルキャット(Pardofelis marmorata)、コロコロ(Leopardus colocola)、ジョフロイネコ(Leopardus geoffroyi)、コドコド(Leopardus guigna)、サザンタイガーキャット(Leopardus guttulus)、アンデスネコ(Leopardus jacobita)、オセロット(Leopardus pardalis)、ジャガーネコ(Leopardus tigrinus)、マーゲイ(Leopardus wiedii)、カナダオオヤマネコ(Lynx canadensis)、オオヤマネコ(Lynx lynx)、スペインオオヤマネコ(Lynx pardinus)、ボブキャット(Lynx rufus)、ベンガルヤマネコ(Prionailurus bengalensis)、ジャワヤマネコ(Prionailurus javanensis)、マレーヤマネコ(Prionailurus planiceps)、サビイロネコ(Prionailurus rubiginosus)、スナドリネコ(Prionailurus viverrinus)、マヌルネコ(Otocolobus manul)、ハイイロネコ(Felis bieti)、イエネコ(Felis catus)、ジャングルキャット(Felis chaus)、リビアヤマネコ(Felis lybica)、スナネコ(Felis margarita)、クロアシネコ(Felis nigripes)、ヨーロッパヤマネコ(Felis silvestris)、及び、これらの亜種が例示されるが、これらに限定されない。
本明細書において、「尿毒素」とは、慢性腎臓病/腎不全が進行するにつれて、血中における濃度が上昇する様々な分子を意味することとする。本明細書における「尿毒素」としては、例えば、インドキシル硫酸(indoxyl sulfate)、無機リン(inorganic phosphorus)、グルカル酸(glucaric acid)、メソエリトリトール(meso-Erythritol)、チオジグリコール酸(thiodiglycolic acid)、アコニット酸(aconitic acid)、グルクロン酸(glucuronic acid)、2-ヒドロキシイソ吉草酸(2-Hydroxyisovaleric acid)、ガラクツロン酸(galacturonic acid)、ホモゲンチジン酸(homogentisic acid)、イノシトール(Inositol)、尿素(urea)、ホスホン酸(phosphonic acid)、アラビノース(arabinose)、マンノース(mannose)、アラビトール(arabitol)、SAA(serum amyloid A protein)、アポリポプロテインB(apolipoprotein B)、KIAA0100、Vacuolar protein sorting-associated protein 53 homolog、アニオン性トリプシン(Anionic trypsin)、IgH可変領域(IgH variable region)、ガレクチン3結合タンパク質(galectin-3-binding protein)、Igλ可変領域(Ig lambda variable region)、凝固第IX因子(coagulation factor IX)、及び、ホスホグリセリン酸ムターゼ(phosphoglycerate mutase)等が挙げられるがこれらに限定されない。
本発明は、Apoptosis inhibitor of macrophage (AIM)、AIMの生物学的活性を有するAIM断片、又は該AIM又はAIM断片をコードする核酸を含む、重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤(以下、「本発明の尿毒症の悪化抑制剤」と称することがある)を提供する。
ここでエステルにおけるRとしては、例えば、メチル、エチル、n-プロピル、イソプロピル、n-ブチルなどのC1-6アルキル基;例えば、シクロペンチル、シクロヘキシルなどのC3-8シクロアルキル基;例えば、フェニル、α-ナフチルなどのC6-12アリール基;例えば、ベンジル、フェネチルなどのフェニル-C1-2アルキル基;α-ナフチルメチルなどのα-ナフチル-C1-2アルキル基などのC7-14アラルキル基;ピバロイルオキシメチル基などが用いられる。
ここで、縮合や保護基の脱離は、自体公知の方法、例えば、以下の(1)及び(2)に記載された方法に従って行われる。
(1)M. Bodanszky及びM. A. Ondetti, Peptide Synthesis, Interscience Publishers, New York(1966年)
(2)Schroeder及びLuebke, The Peptide, Academic Press, New York(1965年)
中枢神経:意識障害、不眠、記憶障害、頭痛、混乱、けいれんなど
末梢神経:末梢神経障害、足の不快感など
消化管:食欲不振、嘔吐、腹部膨満など
肺:呼吸困難、肺水腫、低酸素血症など
心臓又は血管:動悸、高血圧など
代謝:カリウム上昇、アシドーシスなど
眼:視力障害など
血液:貧血など
皮膚:皮下出血、浮腫、色素沈着、掻痒感など。
本発明の変異型ヒトAIMは、好ましくは、以下の(1b)から(5b)のいずれか1つのアミノ酸配列を含む。
(1b)配列番号1で表されるアミノ酸配列のアミノ酸番号191のシステインがセリンに置換されたアミノ酸配列。
(2b)配列番号1で表されるアミノ酸配列のアミノ酸番号300のシステインがセリンに置換されたアミノ酸配列。
(3b)配列番号1で表されるアミノ酸配列のアミノ酸番号191のシステインがセリンに置換され、かつ配列番号1で表されるアミノ酸配列のアミノ酸番号300のシステインがセリンに置換されたアミノ酸配列。
(4b)(1b)から(3b)のいずれか1つのアミノ酸配列と実質的に同一であって、かつ(1b)から(3b)のいずれか1つのアミノ酸配列に存在するシステインおよび該置換されたセリンは残されている、アミノ酸配列。
(5b)(1b)から(3b)のいずれか1つのアミノ酸配列に存在するシステインおよび該置換されたセリン以外の箇所において、さらに1から数個のアミノ酸を欠失、付加、挿入または置換あるいはその組み合わせを含むアミノ酸配列。
尚、野生型組換えAIMと同等又は向上した機能を有するAIM改変体については、特願2017-220733等に開示されるものを用いることができる。
本発明はまた、Apoptosis inhibitor of macrophage (AIM)、AIMの生物学的活性を有するAIM断片、又は該AIM又はAIM断片をコードする核酸を、重度腎不全に罹患するネコ科動物に投与すること含む、重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための方法(以下、「本発明の尿毒症の悪化抑制方法」と称することがある)を提供する。
重度腎不全に罹患するネコに対してAIMを投与し、その影響を確認した。本試験に用いたネコ(n=15)は、次の条件を満たす状態のネコとした:
(1)血中のインドキシル硫酸(IS)の濃度が5μg/mL以上、且つ
(2)血中の無機リン(IP)の濃度が7.5mg/dL以下。
一方で、尿毒素であるIPやISの血中濃度は、腎機能が回復していないにもかかわらず、AIMの投与により上昇が抑制されていた(図3及び図5)。
また、炎症マーカーであるSAAについてもAIMの投与により有意に濃度が低下した(図4)。
健常ネコ、ステージ3bのネコ、リコンビナントマウスAIM(2 mg)又はPBSを2週間おきに計6回静脈投与した後のステージ3bのネコ(Day 70)それぞれ6匹分、さらにリコンビナントマウスAIM投与終了後50日後(Day 120)のネコ3匹分の血清のミックスを、GC-mass spectrometer (MS)及びLC-MSにて解析した。
尚、GC-MS及びLC-MSの解析は以下の方法及び条件で行った。
データベース(SHIMADZU Smart Metabolites Database)に収載されている401種類の成分(メトオキシム化体又はTMS誘導体化物の異性体を含めると568種類の化合物)のうち、試料溶液でピークが検出された化合物をピックアップし、これらの化合物のピーク面積をIS(2-イソプロピルリンゴ酸-3TMS)のピーク面積で割り、IS補正値を算出した。群間比較を行うため、各化合物のIS補正値について、健常ネコの値を1とし、各群の相対値をグラフにした。
比較解析は、各タンパク質において特異な配列のペプチド(Unique peptide)及びRazor Peptides(*)を対象として解析を実施した。各サンプル間のタンパク質量比Abundance Ratioにおいては、それぞれ全タンパク質のAbundance Ratioの中央値にて除することにより規格化した結果を示した。群間比較を行うため、健常ネコの値を1とし、各群の相対値をグラフにした。
(*タンパク質間で共有されるペプチドは、同定ペプチドが最も多いタンパク質由来として割り振られ、これらをRazor Peptidesという。)
理論に拘束されることを望むものではないが、ステージ3bのネコにAIMを投与しても腎機能の改善は見られないことから、AIMによる血中の尿毒素の低減作用は、AIMが直接的に尿毒素に作用し、その結果、当該尿毒素の血中からの排出が促進されている可能性がある。従って、AIMによる血中の尿毒素の濃度の低減は、腎不全のステージやネコに限定されるメカニズムではない可能性が極めて高いと考えられる。従って、AIMの投与による血中の尿毒素の低減は、AIMを有するあらゆる哺乳動物に適用可能であり、また、腎不全のステージも限定されるものではないと考えられる。
Claims (5)
- Apoptosis inhibitor of macrophage(AIM)、AIMの生物学的活性を有するAIM断片、又は該AIM又はAIM断片をコードする核酸を含む、重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤であって、重度腎不全が、血中のインドキシル硫酸の濃度が5μg/mL以上、且つ、血中の無機リンの濃度が7.5 mg/dL以下で定義される、剤。
- Apoptosis inhibitor of macrophage(AIM)、AIMの生物学的活性を有するAIM断片、又は該AIM又はAIM断片をコードする核酸を含む、重度腎不全に罹患するネコ科動物における血中の尿毒素の濃度を低減するための剤であって、重度腎不全が、血中のインドキシル硫酸の濃度が5μg/mL以上、且つ、血中の無機リンの濃度が7.5 mg/dL以下で定義される、剤。
- Apoptosis inhibitor of macrophage(AIM)、AIMの生物学的活性を有するAIM断片、又は該AIM又はAIM断片をコードする核酸を含む、哺乳動物における血中の尿毒素の濃度を低減するための剤。
- 哺乳動物がヒト、ウシ、サル、ウマ、ブタ、ヒツジ、ヤギ、イヌ、ネコ、モルモット、ラット、マウス、ウサギ、又はハムスターである、請求項3記載の剤。
- 哺乳動物がヒトである、請求項3記載の剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022139482A JP2024034914A (ja) | 2022-09-01 | 2022-09-01 | 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 |
PCT/JP2023/031922 WO2024048748A1 (ja) | 2022-09-01 | 2023-08-31 | 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022139482A JP2024034914A (ja) | 2022-09-01 | 2022-09-01 | 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2024034914A true JP2024034914A (ja) | 2024-03-13 |
Family
ID=90097947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022139482A Pending JP2024034914A (ja) | 2022-09-01 | 2022-09-01 | 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2024034914A (ja) |
WO (1) | WO2024048748A1 (ja) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2938944C (en) * | 2014-02-07 | 2020-01-28 | Toru Miyazaki | Apoptosis inhibitor of macrophage (aim) as preventive or therapeutic agent for kidney disease |
JPWO2021079869A1 (ja) * | 2019-10-21 | 2021-04-29 |
-
2022
- 2022-09-01 JP JP2022139482A patent/JP2024034914A/ja active Pending
-
2023
- 2023-08-31 WO PCT/JP2023/031922 patent/WO2024048748A1/ja unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024048748A1 (ja) | 2024-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aoki et al. | Attenuation of bleomycin-induced pulmonary fibrosis by follistatin | |
US7534764B2 (en) | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin | |
JP4855268B2 (ja) | アルツハイマー治療剤 | |
AU2018202783A1 (en) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure | |
JP2009539383A (ja) | 安定化されたインスリン様増殖因子ポリペプチド | |
WO2006045319A2 (en) | Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure | |
Ning et al. | Neamine induces neuroprotection after acute ischemic stroke in type one diabetic rats | |
CA3114869C (en) | Therapeutic agent for neurodegenerative disease | |
WO2024048748A1 (ja) | 重度腎不全に罹患するネコ科動物における尿毒症の悪化を抑制するための剤 | |
WO2024014463A1 (ja) | 腎臓結石の治療または予防剤 | |
EP4378472A1 (en) | Therapeutic agent for ischemic disease | |
JP4839476B2 (ja) | ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途 | |
US20240092861A1 (en) | Cd93 functional domains for use in treating osteoporosis | |
TW202417033A (zh) | 腎臟結石的治療或預防劑 | |
JP2014526440A (ja) | 炎症誘発性状態の治療および予防のためのhdl関連分子の使用 | |
JP2003164298A (ja) | アミロイドβタンパク質産生阻害薬のスクリーニング方法 | |
JP2006298780A (ja) | Hgf遺伝子と粗大凝集アルブミン−ポリエチレンイミン(maa−pei)との複合体 | |
Luo et al. | Ablation of specific insulin‐like growth factor I forms reveals the importance of cleavage for regenerative capacity and glycosylation for skeletal muscle storage | |
JP2023083665A (ja) | マイオネクチンを有効成分とする筋萎縮抑制剤 | |
JP2023017556A (ja) | 機能性ペプチドを有効成分とする筋萎縮抑制剤 | |
JP2014094919A (ja) | 腎炎の予防または治療剤 | |
WO2018191599A1 (en) | Brown fat-selective adipokines | |
JP2013531990A (ja) | アテローム性動脈硬化症治療のための組成物および方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221111 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20231020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240205 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240508 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240514 |